Why behavioural intelligence is becoming the missing strategic capability

For more than three decades, the MedTech industry has invested billions in understanding two things exceptionally well: what clinicians buy and whether technologies deliver the expected clinical outcomes. Yet it has invested remarkably little in understanding the one factor that ultimately determines both: how clinicians actually make decisions in everyday practice.

This imbalance has shaped how companies gather intelligence, allocate resources, and set strategy. Commercial data reveals market adoption. Clinical evidence validates efficacy and value. Both are indispensable. Together, they underpin forecasting, regulatory strategy, reimbursement, portfolio planning, and commercial execution.

However, neither fully explains why clinical practice changes—or when those changes will appear in the numbers. What is missing is a clear understanding of the decisions that sit between strong evidence and real-world market outcomes. Behavioural intelligence is the missing layer that explains how clinical evidence becomes commercial performance.

This challenge is not unique to MedTech. Consumer goods companies have spent decades investing in continuous behavioural tracking to understand purchasing habits, brand perceptions and changing consumer preferences long before those shifts become visible in sales data. MedTech has become highly sophisticated in commercial and clinical intelligence but has been slower to develop an equivalent behavioural capability.

In categories such as advanced wound care, ostomy management, continence care, vascular access and other clinician-driven MedTech areas, decisions involve constant trade-offs that traditional data streams rarely reveal in real time. As care moves into community and home settings and patient complexity rises, the cost of operating without this layer becomes increasingly clear. Companies frequently encounter frustratingly slow adoption curves, persistent unmet needs despite strong clinical evidence, and competitive shifts in directions that cannot be predicted by clinical evidence alone and are identified by existing intelligence systems only once they are already established.

Many companies and leaders within their respective categories sense this limitation. They know frontline behaviour drives everything else, yet they lack a systematic, ongoing view of how it is evolving.

The Three Intelligence Systems